Work

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.lba8505

Authors: Charles M. Rudin, Maria Catherine Pietanza, Todd Michael Bauer, David R. Spigel, Neal Ready, Daniel Morgensztern, Bonnie S. Glisson, Lauren Averett Byers, Melissa Lynne Johnson, Howard A. Burris, Francisco Robert, Donald K Strickland, Hany Zayed, Ramaswamy Govindan, Scott Dylla, Stanford L. Peng

Institutions: Memorial Sloan Kettering Cancer Center, Tennessee Oncology, Sarah Cannon, Duke Medical Center, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center, University of Alabama at Birmingham, Instacart (United States)

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4235451303

Cites:

Cited by: 14

Related to: 10